Cancer therapies have evolved from conventional cytotoxic chemotherapy to targeted drugs that interfere with specific molecules involved in tumour growth. Targeted drugs that inhibit the epidermal growth factor (EGF) receptor have been successfully tested and are in clinical use for various cancers. Dermatologic toxicity is a unique characteristic of this class of drugs.
Skin tags are composed of an overgrowth of normal epithelial cells, which enclose a dermal connective tissue stalk made up of loose, edematous collagen fibres, blood cells and sometimes fat cells.
